After a long hiatus, i am back with a bang....life was becoming pretty hectic as i was required to change job, city and home....so after long time i am blogging something.....
Pharma industry there were acquisitions happening, but not like the big ones which happened last decade. Valeant was in a spree for deal, like wise Bayer moving ahead with its M&A deal. Pfizer was playing safe. Like Abbott last year split its division into two, like wise Pfizer and Eli lilly decided to move ahead with split and consolidation of some of its BU units.
Medical devices industry there were lot of M&A activity and approvals, but we have more to look forward in this year from the emerging markets
Biosimilars were creating lot of noise, with the first biosimilar in immunology approved in EU, this year we need to look at the market. Both physician's and patients response to the drug in terms of its safety and efficacy.
Companies in 2014 to watch : Celltrion, the biggest CMO for biologics/Biosimilars. Is it really there for sale?
Roche is continuously bolstering its Oncology portfolio.
More to come in Next article......
Pharma industry there were acquisitions happening, but not like the big ones which happened last decade. Valeant was in a spree for deal, like wise Bayer moving ahead with its M&A deal. Pfizer was playing safe. Like Abbott last year split its division into two, like wise Pfizer and Eli lilly decided to move ahead with split and consolidation of some of its BU units.
Medical devices industry there were lot of M&A activity and approvals, but we have more to look forward in this year from the emerging markets
Biosimilars were creating lot of noise, with the first biosimilar in immunology approved in EU, this year we need to look at the market. Both physician's and patients response to the drug in terms of its safety and efficacy.
Companies in 2014 to watch : Celltrion, the biggest CMO for biologics/Biosimilars. Is it really there for sale?
Roche is continuously bolstering its Oncology portfolio.
More to come in Next article......
No comments:
Post a Comment